Satellos Bioscience Inc. MSLE
6.69 USD +0.34 (+5.35%)
Nov 6, 2026, 11:22 AM EST
6.42 Day range 6.92
5.30 52-week range 13.40
- YTD
- +13.78%
- 1 year
- +17.37%
- Market cap
- 141.94M
- EPS (ttm)
- -1.95
- YTD return
- +13.78%
- 1-year return
- +17.37%
- Volume
- 71.07K
- Avg volume
- 42.05K
- Open
- 6.57
- Previous close
- 6.35
- Day's range
- 6.42 – 6.92
- 52-week range
- 5.30 – 13.40
2Y -0.48 (-6.62%)
Financials — quick view
MSLE Revenue — quarterly 0
MSLE Net income — quarterly -11.72M
MSLE EPS — quarterly -0.56
News
Satellos Bioscience Switches BASECAMP Phase 2 Primary Endpoint To MRI Fat Fraction Following FDA Feedback - Craig-Hallum Initiates Coverage On Satellos Bioscience with Buy Rating, Announces Price Target of $24
Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform 
Satellos Bioscience Completes Enrollment For BASECAMP, Phase 2 Clinical Trial Evaluating Forazapadin For Treatment Of Duchenne Muscular Dystrophy In Ambulatory Boys 7 To 10 Years Of Age 
FDA Clears Satellos Bioscience’s IND Application For Forazapadin For Treatment Of Facioscapulohumeral Muscular Dystrophy - HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
- Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
HC Wainwright & Co. Maintains Buy on Satellos Bioscience, Raises Price Target to $18 
Satellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on MSLE — it syncs with the Stock Master app.